Abivax (STU:2X1) Long-Term Debt : €52.16 Mil (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Abivax Long-Term Debt?

Abivax's Long-Term Debt for the quarter that ended in Dec. 2024 was €52.16 Mil.

Abivax's quarterly Long-Term Debt increased from Jun. 2023 (€24.47 Mil) to Dec. 2023 (€26.62 Mil) and increased from Dec. 2023 (€26.62 Mil) to Dec. 2024 (€52.16 Mil).

Abivax's annual Long-Term Debt increased from Dec. 2022 (€8.29 Mil) to Dec. 2023 (€26.62 Mil) and increased from Dec. 2023 (€26.62 Mil) to Dec. 2024 (€52.16 Mil).

Abivax Long-Term Debt Historical Data

The historical data trend for Abivax's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abivax Long-Term Debt Chart

Abivax Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Debt

Get a 7-Day Free Trial

33.98

34.61

8.29

26.62

52.16

Abivax Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Dec24
Long-Term Debt	Get a 7-Day Free Trial															48.84	8.29	24.47	26.62	52.16

Abivax (STU:2X1) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Abivax Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Abivax's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Abivax Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (STU:2X1) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

ABVX:USA AAVXF:USA 0RA9:UK ABVX:France 2X1:Germany

Address

7-11 boulevard Haussmann, Paris, FRA, 75009

Website

https://www.abivax.com

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Abivax Headlines

No Headlines